Comparison of Sorafenib versus Hepatic Arterial Infusion Chemotherapy-Based Treatment for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Sorafenib is the first approved systemic treatment for advanced hepatocellular carcinoma (HCC). However, its clinical utility is limited, especially in Asian countries. Several reports have suggested the survival benefits of hepatic arterial infusion chemotherapy (HAIC) for advanced HCC with main po...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Gut and liver Ročník 15; číslo 2; s. 284 - 294
Hlavní autoři:	Ahn, Young Eun, Suh, Sang Jun, Yim, Hyung Joon, Seo, Yeon Seok, Yoon, Eileen L., Kim, Tae Hyung, Lee, Young Sun, Yim, Sun Young, Kim, Hae Rim, Kang, Seong Hee, Jung, Young Kul, Kim, Ji Hoon, Yeon, Jong Eun, Um, Soon Ho, Byun, Kwan Soo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Korea (South) Editorial Office of Gut and Liver 15.03.2021 Gastroenterology Council for Gut and Liver 거트앤리버 소화기연관학회협의회
Témata:	Antineoplastic Combined Chemotherapy Protocols carcinoma Carcinoma, Hepatocellular - complications Carcinoma, Hepatocellular - drug therapy chemotherapy hepatic artery hepatocellular Humans Liver Neoplasms - complications Liver Neoplasms - drug therapy Original Portal Vein portal vein thrombosis sorafenib Sorafenib - therapeutic use Thrombosis Treatment Outcome 내과학 Hepatic artery Chemotherapy Carcinoma Sorafenib Portal vein thrombosis hepatocellular
ISSN:	1976-2283, 2005-1212, 2005-1212
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!